Renal Health Dashboard

The dashboard outcome is not a diagnosis produced by software. It is a more reliable clinical conversation: what was measured, when it was measured, how trustworthy it is, and what should happen next. Ask yourself: when the next patient with diabetes appears on the renal register, can the team see both eGFR and albuminuria, their dates, and their direction of change on one screen?

How diabetic kidney disease progresses

Diabetic kidney disease develops when long-term metabolic and vascular stress affects the kidney’s small blood vessels and filtering units, called glomeruli. High blood glucose can alter the vessel wall and increase pressure within the glomerulus. High blood pressure adds further strain. Over time, the filtration barrier may allow albumin to pass into urine, while the number of functioning filters gradually falls.

This process is not always linear. Albuminuria may increase before eGFR changes noticeably, and eGFR may decline without a large albumin result. A single abnormal result also does not establish a persistent stage. Fever, urinary infection, strenuous exercise, uncontrolled blood pressure, heart failure, dehydration, menstruation, and some medicines can affect urine albumin or creatinine measurements. The dashboard should therefore record context, not only the value.

Albuminuria is commonly reported using the urine albumin-to-creatinine ratio (UACR), measured in milligrams of albumin per gram of creatinine (mg/g). The broad categories are:

• A1: less than 30 mg/g, normal to mildly increased; - A2: 30-300 mg/g, moderately increased; - A3: more than 300 mg/g, severely increased.

Some Kenyan laboratories report UACR in milligrams per millimole (mg/mmol). The system should store the unit and display the laboratory’s reference range rather than silently treating all values as interchangeable. If conversion is required, it should be validated by the laboratory team and documented in the dashboard specification.

eGFR estimates how much blood the kidneys filter each minute, adjusted to a standard body-surface area. It is usually reported in millilitres per minute per 1.73 square metres (mL/min/1.73 m²). The usual chronic kidney disease categories are:

• G1: 90 or higher; - G2: 60-89; - G3a: 45-59; - G3b: 30-44; - G4: 15-29; - G5: less than 15.

G1 and G2 do not, by themselves, establish chronic kidney disease when there is no other evidence of kidney damage. Albuminuria, structural abnormalities, urine sediment findings, or a persistent fall in kidney function may provide that evidence. Chronicity generally requires abnormality for at least three months, supported by repeat results or other clinical information.

The two measures work best as a pair. A person with eGFR 75 and UACR 420 mg/g has a different monitoring concern from someone with eGFR 35 and UACR 20 mg/g. Both require attention, but the likely risks and follow-up priorities differ. The Kidney Stage Compass should display the eGFR category and albuminuria category side by side, with the date of each test and a flag when either result is missing or too old to interpret confidently.

Risk factors that commonly accelerate progression include:

1. persistent high blood glucose and high blood pressure; 2. increasing or persistent albuminuria; 3. established cardiovascular disease or heart failure; 4. smoking, obesity, and limited physical activity; 5. episodes of acute kidney injury, infection, dehydration, or exposure to kidney-harming medicines; 6. delayed follow-up because of cost, transport, referral, or laboratory access.

These factors do not predict an individual outcome with certainty. They help the team decide how closely to monitor and which gaps require attention. The key takeaway is simple: eGFR measures filtration, UACR measures leakage, and neither should be interpreted without timing, units, and clinical context.

Applying the Kidney Stage Compass in practice

Begin with a complete baseline record. For a patient with diabetes entering the renal monitoring pathway, capture the date of diabetes diagnosis when known, blood pressure, serum creatinine, calculated eGFR, UACR, urine test conditions, current medicines, and relevant acute illness. Record whether the sample was collected during fever, urinary symptoms, visible blood in urine, heavy exercise, or another condition that may affect interpretation.

For patients with diabetes who have not previously been assessed, arrange kidney screening at least annually when local resources permit, using eGFR and UACR. If either test is abnormal, repeat testing should be planned rather than left to chance. A mildly or moderately increased UACR should generally be confirmed with repeat samples over the following three to six months, avoiding collection during an acute illness or other known confounding condition. Persistent abnormality is more meaningful than one isolated result.

For established chronic kidney disease, the review interval should reflect both eGFR and albuminuria. A practical hospital protocol may use the following starting points, subject to clinician review and local capacity:

| Kidney Stage Compass result | Suggested monitoring approach | |---|---| | eGFR 60 or higher with UACR below 30 mg/g and stable results | Review at least annually | | eGFR 60 or higher with UACR 30-300 mg/g | Review about every 6 months; confirm persistence | | eGFR 60 or higher with UACR above 300 mg/g | Review about every 3-6 months | | eGFR 45-59 | Review about every 3-6 months, depending on trend and albuminuria | | eGFR 30-44 | Review at least every 3 months and consider nephrology input | | eGFR 15-29, or a rapid decline | Prompt nephrology review and a documented management plan | | eGFR below 15 or kidney-failure symptoms | Urgent specialist assessment |

These are operational starting points, not automatic orders. The responsible clinician should adjust timing for age, comorbidity, pregnancy, acute illness, medication changes, access barriers, and the reliability of the laboratory result.

Trend is often more useful than a single stage label. The dashboard should calculate the time between results and show whether eGFR is stable, falling, or changing too quickly to explain. A sustained decline of approximately 5 mL/min/1.73 m² or more in one year, or a fall of 25% or more from baseline, warrants clinical review and confirmation. A sudden fall should be assessed sooner because acute kidney injury, obstruction, infection, dehydration, or medicine-related harm may be contributing.

The alert design should support action without creating unnecessary alarm. For example, a red flag may indicate eGFR below 30, UACR above 300 mg/g, a confirmed rapid decline, or a missing repeat test after an abnormal result. The alert should show the latest value, previous value, dates, laboratory source, and the assigned action owner. “Review required” is more useful than an unexplained colour change.

Staff should also know when same-day or urgent clinical assessment is needed. Escalate promptly for markedly reduced urine output, worsening breathlessness or swelling, confusion, severe weakness, persistent vomiting, chest pain, severe blood pressure elevation with symptoms, or a rapid creatinine rise. These findings may indicate an acute problem and should not wait for the next routine dashboard review.

For administrators, implementation depends on data discipline. Define one source of truth for creatinine and UACR, retain original units, record sample dates separately from result-entry dates, and audit missingness monthly. A simple dashboard view can include patient identifier, latest eGFR and UACR, categories, previous values, trend arrows, next review date, and unresolved alerts. Each abnormal result should have a documented owner and due date.

The practical sequence is: verify the result, classify eGFR and UACR, check chronicity, review the trend and context, assign the next interval, and document escalation when thresholds are crossed. That sequence turns laboratory data into dependable follow-up.

Avoiding common staging errors

Treating one abnormal result as permanent chronic kidney disease

Why it happens: A busy clinic may receive an abnormal eGFR or UACR and immediately assign a chronic stage. Acute illness, dehydration, infection, or laboratory variation can produce a temporary change.

What to do instead: Record the result as abnormal but unconfirmed, document the clinical context, and schedule repeat testing. Use persistence over at least three months, where appropriate, before treating the finding as established chronic disease. If the result is severely abnormal or the patient is unwell, arrange prompt clinical assessment rather than waiting for routine confirmation.

Using eGFR without UACR

Why it happens: Creatinine is often easier to order or appears automatically in the laboratory system, while urine albumin testing may be unavailable, overlooked, or stored in a separate record.

What to do instead: Make eGFR and UACR paired fields in the Renal Health Dashboard. Display “not done” separately from “normal.” For every patient with diabetes, track whether both tests were completed within the planned screening interval. A normal eGFR does not remove the need to look for albuminuria.

Comparing results without checking dates, units, or laboratory method

Why it happens: Imported results may combine mg/g and mg/mmol, or compare a new value with an old result entered weeks after collection. Creatinine-based eGFR may also be calculated using different equations.

What to do instead: Preserve the collection date, reporting laboratory, unit, and calculation method. Configure the dashboard to prevent silent unit mixing and to display a warning when methods differ. Before acting on a sharp change, confirm that the values are comparable and repeat testing when clinically appropriate.

Letting alerts replace clinical review

Why it happens: A colour-coded dashboard feels decisive, especially when staffing is limited. Yet an alert cannot assess symptoms, fluid status, medicines, or the possibility of acute kidney injury.

What to do instead: Attach every alert to a defined review pathway: who reviews it, within what time, what information they check, and how the outcome is recorded. Use the dashboard to focus attention, not to make an unsupported diagnosis or treatment decision.

The Kidney Stage Compass is most useful when it makes uncertainty visible. A dated, unit-checked trend with a clear follow-up owner is safer than a precise-looking stage built from incomplete data. When eGFR and albuminuria are brought together in that way, the Renal Health Dashboard becomes more than a results display: it becomes a practical bridge between laboratory measurement, clinical judgment, and timely kidney care in the referral hospital.

End of chapter one. 4 more chapters in the full book.